View from a cancer center.
As part of Healthplan's genomics series, we have sought opinion and perspective from various sectors of health care. Articles in past issues have reflected both the enthusiasm and optimism of the genomics industry as well as the caution and concerns of health plan medical directors confronted with the question of who will pay for the new genetic services and treatments and--more importantly--how they will truly benefit patients. In this issue, we publish the perspective and goals of doctors and researchers at a renowned cancer center. As our series unfolds, it is becoming increasingly clear that a national dialogue is needed on the important questions raised by the authors in our genomic series. Readers are encouraged to send their views on this topic to Healthplan.